Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties by Menden, Michael P. et al.
 
Machine Learning Prediction of Cancer Cell Sensitivity to Drugs
Based on Genomic and Chemical Properties
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Menden, Michael P., Francesco Iorio, Mathew Garnett, Ultan
McDermott, Cyril H. Benes, Pedro J. Ballester, and Julio Saez-
Rodriguez. 2013. Machine learning prediction of cancer cell
sensitivity to drugs based on genomic and chemical properties.
PLoS ONE 8(4): e61318.
Published Version doi:10.1371/journal.pone.0061318
Accessed February 19, 2015 12:08:10 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11179049
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAMachine Learning Prediction of Cancer Cell Sensitivity to
Drugs Based on Genomic and Chemical Properties
Michael P. Menden
1, Francesco Iorio
1,2, Mathew Garnett
2, Ultan McDermott
2, Cyril H. Benes
3,
Pedro J. Ballester
1*, Julio Saez-Rodriguez
1*
1European Bioinformatics Institute, Wellcome Trust Genome Campus–Cambridge, Cambridge, United Kingdom, 2Cancer Genome Project, Wellcome Trust Sanger
Institute, Wellcome Trust Genome Campus--Cambridge, Cambridge, United Kingdom, 3Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center
and Harvard Medical School, Charlestown, Massachusetts, United States of America
Abstract
Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should ultimately lead to a
personalised treatment. High-throughput screenings of potentially active compounds against a panel of genomically
heterogeneous cancer cell lines have unveiled multiple relationships between genomic alterations and drug responses.
Various computational approaches have been proposed to predict sensitivity based on genomic features, while others have
used the chemical properties of the drugs to ascertain their effect. In an effort to integrate these complementary
approaches, we developed machine learning models to predict the response of cancer cell lines to drug treatment,
quantified through IC50 values, based on both the genomic features of the cell lines and the chemical properties of the
considered drugs. Models predicted IC50 values in a 8-fold cross-validation and an independent blind test with coefficient of
determination R
2 of 0.72 and 0.64 respectively. Furthermore, models were able to predict with comparable accuracy (R
2 of
0.61) IC50s of cell lines from a tissue not used in the training stage. Our in silico models can be used to optimise the
experimental design of drug-cell screenings by estimating a large proportion of missing IC50 values rather than
experimentally measuring them. The implications of our results go beyond virtual drug screening design: potentially
thousands of drugs could be probed in silico to systematically test their potential efficacy as anti-tumour agents based on
their structure, thus providing a computational framework to identify new drug repositioning opportunities as well as
ultimately be useful for personalized medicine by linking the genomic traits of patients to drug sensitivity.
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Introduction
High-throughput screening of a large number of molecules is a
widely used approach to identify lead compounds exerting a
beneficial effect on a given phenotype. In the context of cancer,
libraries of chemical entities have been tested in this way against
panels of cell lines grown in different conditions and with
heterogeneous genomic backgrounds [1]. Following the pioneering
work of the ‘‘NCI-60’’, a collection of 59 human cancer cell lines
developed by the National Cancer Institute for in vitro drug
screening [2], recent hallmark studies have shown that screening
very large cell line collections can recapitulate known and identify
novel molecular genomic determinants of drug sensitivity [1,3–5].
In these studies, using systematic statistical inference and
regression methods, determinant such as oncogenic lesions, high
or low levels of basal gene expression and other genotypic traits
have been associated to profiles of increased sensitivity/resistance
to specific compounds. For instance, by applying a multivariate
analysis of variance [6] and the ‘Elastic Net’ regression framework
[7] established drug-genotype associations have been confirmed
and complemented with markers of tissue-specificity and novel
connections, e.g. the EWS-FLI1 translocation in Ewing’s sarcoma
and sensitivity to PARP inhibitors, have been identified and further
experimentally validated. Results of these studies have been made
publicly available, providing unique resources that support the
discovery of new predictive biomarkers for personalised cancer
therapy.
Increasing further the size of the considered cell-line/compound
panels would be very beneficial, as it provides the basis to improve
the accuracy and predictive power of the inferred associations.
However, this requires larger infrastructures and the cost grows
with the screening size. In addition, due to various technical and
logistical reasons in a high-throughput screen [7], the resulting
compound-by-cell line matrix of drug efficacy (typically summa-
rised in their IC50, the half maximal (50%) inhibitory concentra-
tion of a substance with respect to cell viability) is often not
complete. Although many steps are automated, filling experimen-
tally each gap could be expensive and laborious [6]. Hence, an
accurate tool to impute missing IC50s and estimate them for novel
cell lines would be of great value for drug screening design.
Furthermore, a robust prediction tool for in silico identification
of potentially effective drugs for treating a specific cancer could be
used for drug repositioning [8,9]. An approach of this kind is
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response profiles of the NCI-60 screening, through a ‘guilt-by-
association’ paradigm. Following this principle, drugs eliciting a
similar drug-response profile across the cell lines in the NCI-60
panel are hypothesized to share a common mode of action (MoA),
thus enabling MoA discovery for novel drugs (if their tumour-
suppression profile is similar to that of a known and well
characterized drug) as well as the discovery of novel or secondary
effects for established drugs.
Ultimately, in silico methods to accurately predict the effective-
ness of drugs based on the molecular making of tumours (i.e.
genome, transcriptome) would be a major milestone towards
personalized therapies for cancer patients based on molecular
biomarkers [12].
Results
We therefore investigated whether it is possible to build
machine learning models (for details see ‘‘Materials and Methods’’
section, ‘‘Machine learning’’ subsection) that can predict drug
sensitivity using cell line screening experimental data, where cell
lines are treated with variable concentration of a given drug and
the resulting dose-response curve summarized by an IC50.W e
focused on the most comprehensive cancer drug screening dataset
available to date, from the ‘‘Genomics of Drug Sensitivity in
Cancer’’ (GDSC) project [3]. For each drug, a neural network
model was trained to predict its IC50 profile across the panel of cell
lines based on the genomic background of each cell, as
characterised by microsatellite instability status (1= unstable or
0= stable), somatic coding variants in the coding sequence of 77
cancer genes (1= any change in protein sequence and 0= wild
type) and copy number alterations denoting gene amplification
and deletion of those cancer genes (1= amplification/more than 7
copy numbers, 0= wild type/between 1 or 7 copy numbers, and –
1= deletion/no copy number). However, the predictive power of
these initial models was limited, especially for those drugs without
a well-known oncogene-to-drug response dependency.
We reasoned that cancer cell sensitivity to drug molecules is
driven by features from both cells and drugs. Whereas cell features
are ultimately connected to the inner workings of the cell, drug
features include physicochemical properties that are correlated
with the ability of the molecule to cross the cell membrane (e.g.
lipophilicity) or its selectivity to intracellular targets (e.g. finger-
prints encoding the chemical structure).
Indeed, extensive work has been done on Quantitative
Structure-Activity Relationship (QSAR) approaches to predicting
whole-cell activity of molecules based of their chemical properties
[13–16], including applications to predicting anti-cancer activity in
drugs [17,18]. However, such QSAR approaches exclusively
based on chemical features cannot distinguish between resistant
and sensitive cell lines. For instance, building a model without any
information of the cell lines, the model will be not capable of
predicting cell line A to be more resistant than cell line B to drug
C, which is the main aim of integrating chemical and genomic
features in our models.
We therefore extended our machine learning models to include
as input chemical features from the drugs, besides the molecular
characterization of the cell lines (see Fig 1). This integrative
approach not only integrates two complementary streams of
information, but also allows the model to be trained with much
larger amounts of data, which is often a key factor to improve
predictive performance (see Fig 2). Consequently, data was pre-
processed to include 689 chemical descriptors of the drugs and 138
genomic features for differentiating the cell lines, resulting in an
input space of 827 features.
Chemical descriptors were generated with PaDEL software [19]
from simplified molecular-input line entry system (SMILES)
structures. Descriptors include physicochemical features such as
weight, lipophilicity, rule of five, and additionally fingerprints of
the drugs (for details see ‘‘Materials and Methods’’ section,
‘‘Features’’ subsection, and http://padel.nus.edu.sg/software/
padeldescriptor/).
For building our model, we used GDSC screening data from
608 genomically characterised cell lines and 111 drugs for which
chemical information were available (see Fig 2 and Methods for
details). The published version of this matrix holds 38,930 IC50
values (,58% of the total, due to technical and logistic reasons).
We performed an 8-fold cross-validation, where the test set of
each fold was not used for training so as to measure the predictive
power of the resulting models across all drugs rather than for each
drug separately. Neural networks were able to impute missing
log(IC50) values on the test sets with an averaged Pearson
correlation coefficient (Rp), coefficient of determination (R
2) and
root mean square error (RMSE) (Text S1) of 0.85, 0.72 and 0.83
across all 111 drugs, respectively (Fig 3A). Alternatively, random
forests achieved comparable performances (Rp of 0.85, R
2 of 0.72
and RMSE of 0.84; full details in supplementary materials).
Furthermore, we conducted a blind test using 13,565 new
experimental IC50 values only received after training our models
in order to verify our cross-validation results (drug-to-cell line
matrix updated by ,18%, with these newly generated IC50s
exclusively used as the blind test set). The results on the blind test
were almost as good as in the cross-validation, obtaining an Rp of
Figure 1. IC50 prediction workflow. Our method is based on two different input streams: (1) cell line features of 77 oncogenes and their mutation
state, (2) drug features that are generated with PaDEL software [19] from the simplified molecular-input line entry system (SMILES), see method
section for details. The continuous IC50 value is predicted with state-of-the-art machine learning algorithms (neural networks and random forests).
doi:10.1371/journal.pone.0061318.g001
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2 of 0.64 and an RMSE of 0.97 (Fig S1, Text S2). The
accuracy of the predictions encouraged us to train the networks
with fewer IC50 values. Remarkably, the predictive power of the
models did not fall appreciably off in quality, even if the amount of
training data was reduced to 20% of the total (Fig 3B).
Using an analysis of variance (ANOVA) to identify drug-to-
oncogene associations, we investigated how well the IC50 values
predicted for the test set using our model recapitulate associations
manifested in the experimental data, for instance, whether a given
mutation is causing sensitivity or resistance against a drug [3].
Using only predicted IC50 values, we correctly captured 79%
(168/213) of the significant observations with the same t-test
tendency (positive or negative effect on drug sensitivity) identified
with the experimental IC50s. When only considering significant
associations from our model (p-value adjusted with Benjamini-
Hochberg, FDR=0.2), we correctly predicted 28% (59/213) of all
experimentally identified associations. Where we failed to detect
an association the ANOVA effect size is often small, or the
experimental correlation is associated with a mutation either not
or infrequently represented within the subset of cell lines with
predicted IC50 values. Notably, as example of the utility of this
approach, using only predicted IC50 values we identified known
drug-to-oncogene associations such as sensitivity of BRAF-mutated
cells lines to MEK1/2-inhibitors (Fig 4B) [20]. The range of
predicted IC50 values for a drug are typically narrower than for the
observed values and is likely because currently available genomic
dataset are in sufficient to explain the observed range of drug
responses across the cell lines.
In addition, we assessed the predictive power of our model for
unknown cell lines. Therefore, we applied a more stringent 8-fold
cross-validation, where a cell line was either included in the train
or test set. These models achieved an Rp of 0.82, R
2 of 0.68 and an
RMSE of 0.89 (Fig S2) demonstrating the accuracy of our model
to predict IC50 values for completely new cell lines. In an
additional simulation, we left out all cancer cell lines from a
specific tissue, e.g. we removed all lung cancer cell lines (106 out of
608 cell lines) and still obtained an Rp of 0.79, R
2 of 0.61 and
RMSE of 0.99 (Fig S3).
Discussion
Our results show that by using genomic features from the cell
lines and chemical information from drugs, it is possible to build in
silico multi-drug models to impute missing IC50 values with non-
parametric machine learning algorithms such as neural networks
and random forests. As output for our method, we chose to
explore IC50 values as generated by Garnett et al. [3], which
enables us to compare our results to them, however other metrics
(such as a capped IC50 or area under the curve), might provide
additional insight and potentially lead to more robust models.
Figure 2. Comparison of single-drug models and the multi-drug model. The performance of the multi-drug model (red asterisk) and the
family of 111 single-drug models (blue histogram) is represented using three different metrics: (A) Pearson correlation Rp, (B) coefficient of
determination R
2, and (C) root mean square error RMSE.
doi:10.1371/journal.pone.0061318.g002
Figure 3. IC50 prediction. Predictions are achieved with 8-fold cross-
validations. Performance values are exclusively calculated on the test
sets. (A) Correlation between predicted to experimental observed
log(IC50) values (Pearson correlation Rp=0.85 ; coefficient of determi-
nation R
2=0.72, root mean square error RMSE =0.83). Although there is
an enrichment of resistant cell lines, which tend to have higher log(IC50)
values than sensitive cell lines, the lower log(IC50) values are still
decently predicted. (B) Expected improvement of the IC50 prediction by
filling experimentally gaps in the cell-to-drug matrix. The vertical grey
line corresponds to the published data set (filled to ,58%, due to
logistic reasons), which corresponds to the results in panel (A).
However, similar accuracies (Rp of 0.84 instead of 0.85, R
2 of 0.70
instead of 0.72) can be achieved using exclusively 20% of the whole
matrix.
doi:10.1371/journal.pone.0061318.g003
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nation (Fig. 2B) of the multi-drug model are significantly better
than the single-drug models, while the RMSE error is similar (Fig
2C). This means that the error (on average) of predicting a given
IC50 value is the same in the multi-drug and single-drug models
(RMSE) and, since some drugs are active at different concentra-
tion ranges, the model is able to cover a much larger dynamic
range with a similar precision. The coefficient of determination
balances these two terms, and thus a broader range with the same
RMSE increases R
2. Thanks to the use of chemical descriptors,
multi-drug models are trained with a volume of data that is two
orders of magnitude bigger than the data to train each single-drug
model. This larger dataset weights the difficulty in training
heterogeneous response values across drugs.
In several instances, the use of multi-drug models permitted the
in silico identification of genomic events associated with altered
drug sensitivity, which is only possible when genomic properties
are considered.
Although our models did not capture all known gene to drug
associations, we anticipate that as larger drug sensitivity and
genomic datasets become available in coming years the predictive
power of these models will increase. We believe that the predictive
power of our models is due to the large number of cell lines and
broad range of drugs in the GDSC panel that samples intensively
the chemical space of common cancer drugs (chemotherapeutic
and kinase inhibitors). It remains to be determined how these
models will predict completely unknown families of therapeutic
agents.
The predictive ability of our methods for individual values is still
limited and could be further improved by extending the set of
input features with additional layers of molecular characterization
of the cell lines, such as basal transcriptional profiles and
phosphoproteomic data. These data types have been used to
predict drug responses in various contexts [21–24]. Another
valuable extension could be the inclusion of gene expression data
following drug treatment, a powerful in silico resource for
predicting treatment outcomes and elucidating compound mode
of action [25,26], as well as a promising gateway to the
identification of new drug repositioning opportunities [27].
Additionally, epigenetics data could enhance the prediction
capabilities of future methods [28].
Our method uses purely experimental data, but additional
predictive power can be expected from including knowledge of the
underlying network [29]. It has been shown that the prediction of
drug response and mode of action by transcriptional profiling is
significantly enhanced when paired with known a priori gene and
protein networks [30,31] and drug similarities have been inferred
based on the corresponding in silico predicted impinged pathway
[32]. Prior knowledge could also increase the interpretability of the
results. Known regulatory relationships between genes and
transcriptional data [33] and protein networks [34] can be used
to identify deregulated pathways, and be further linked to the
Figure 4. Comparing ANOVA with prediction. (A) Analysis of variance (ANOVA) of experimental data and predicted output for drug-to-
oncogene associations (20% FDR). The size of each association (dot) is proportional to the amount of treated cell lines containing the particular
mutated oncogene. Blue dots indicating the same t-test tendency in our predictions, and red ones the opposite. (B) Predicted and measured IC50so f
BRAF-mutated vs. wild-type cell lines exposed to the MEK1/2-inhibitor PD-0325901 (p- value of prediction =1.91610
205, t-test multiple hypothesis
corrected with Benjamini & Hochberg).
doi:10.1371/journal.pone.0061318.g004
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of importance for drug response.
Incorporation of these additional features will require a scheme
to prioritize the input features based on their impact on the final
trained model. Associations between features and outcomes could
be explicitly unveiled by integrating in our models feature
selections criteria and dimensionality reduction techniques.
In terms of predictive models, we have used standard machine
learning methods (neural networks and random forests), given
their flexibility and robustness as predictive models. A fertile
ground for further research is investigating the application of other
modeling techniques, including linear regression methods (e.g.
LASSO, ElasticNets).
Our results also show that one can estimate the accuracy of
prediction for different degrees of sparseness in the data, which
may have utility when designing experiments where coverage has
to be balanced with accuracy. Furthermore, because models are
able to predict IC50 on cell lines not screened yet, predictions from
these models can be used to decide whether it is worthwhile
expanding the panel of cell lines, or rather focus on a few selected
ones.
The implications of our results go beyond their utility to
optimise the experimental design of drug screenings. Once a
model is built, it could be used to systematically test the potential
effect of novel drugs in silico, based on their chemical features and
similarity. These predictions can help to evaluate the potential
activity of new drugs, e.g. from large chemical libraries, to be
screened. Furthermore, predictions on clinically approved drugs is
expected to reveal candidates for drug repurposing and potentially
identify specific disease sub-types that would be most responsive
[8]. Although cell lines are not an exact replica of real tumours,
comprehensive predictive models such as ours together with
expanded genomic and epigenomic datasets may be a good proxy
to facilitate the development new therapeutic strategies tailored to
individual patients [12].
Materials and Methods
Training dataset
We used the data from the Genomics of Drug Sensitivity in
Cancer project [3], which contains 639 cancer cell lines, each of
them characterised by a set of genomic features (details in the next
section). The characterisation is not complete for every cell line,
and therefore we filtered out cell lines with more than 15 missing
genomic features, which reduced the set of selected cell lines from
639 to 608. The dataset contains 131 drugs. As our method
exploits the chemical structure of each drug, this information in
simplified molecular-input line entry system (SMILES) format is
required. Therefore, we did not consider the 20 drugs for which
SMILES were not available, and built our model for the
remaining 111 drugs.
The resulting matrix of 608 cell lines by 111 drugs will have
67,488 possible drug response curves, each summarised by its IC50
value (drug concentration in mM units required to eradicate 50%
of the cancer cells). Currently, the dataset contains 38,930 IC50
values out of these 67,488 (58%), with missing values mostly due to
logistic reasons such as co-ordinating measurements from various
screening centres. The log IC50 ranges from –7.40
(IC50,4N10
28 M; the most sensitive drug-cell combination) to
6.91 (IC50,8N10
6 M; the most resistant). Note that extremely large
and small values are extrapolations in the IC50 that have no
clinical relevance. We use these ranges in this study as those are
the ones used in the paper Garnett et al. [3] that we compare our
results against.
Blind test dataset
We generated test sets during the cross-validation for estimating
the expected error (details in cross-validation section). However,
even cross-validation can overestimate the prospective perfor-
mance of machine learning methods. Therefore, we conducted a
truly blind test in order to demonstrate the prospective capabilities
of our cross-validated models to impute missing IC50 values in the
608 cell lines by 111 drugs matrix (Fig S1). Our blind test contains
13,565 newly generated IC50 values, which were obtained after
training took place, or put it differently, a batch of new
experimental data was generated to independently validate our
models. To sum up, 58% of the IC50 values are in the original
dataset (used for cross-validation), an additional 18% are used for
the blind test (independent test).
Features
There are two different input data streams in our method: the
genomic background for each cancer cell line, and the chemical
properties of a drug. For the first input data stream, cancer cell
lines are characterised by the mutational status of 77 oncogenes,
where each of them is further described by copy number variation
(any high grade amplification or homozygous deletion of a cancer
gene) and sequence variation (changes in the protein sequence, e.g.
non-synonymous single nucleotide polymorphism). Additionally,
there is one binary feature for the microsatellite stability status of
each cell line. The cell line features were encoded as followed:
Microsatellite instability status ~
1, if unstable
0, if stable
 
Sequence variation ~
1, if mutation
0, if wildtype
 
Copy number variation ~
1
0
{1
,if amplification
,if wildtype
,if deletion
8
<
:
All mutations considered, we have 77 possible copy number
variations plus 77 possible sequence variations and one microsat-
ellite stability value, which sums up to 155 possible cell line
features. However, a few mutational features are missing for some
cell lines, and we conservatively removed a feature in case it was
missing for any cell line. This led to a final set of 138 genomic
features characterising each cancer cell line.
The second input data stream incorporates 1D and 2D
chemical properties of each drug. We generated these chemical
features using the PaDEL software (v2.11, downloaded from the
project website, http://padel.nus.edu.sg/software/
padeldescriptor/) [19] from the SMILES with default settings.
722 features are physicochemical descriptors and 881 are obtained
from the fingerprints, leading to a total of 1603 chemical features.
We only included chemical features that could be calculated for all
drugs. Furthermore, we removed any feature with the same value
across all drugs, obtaining a final set of 689 chemical features for
each drug (e.g. atom count, bond count, molecular weight, xlogP
or PubChem fingerprint, to name a few). The list of drugs is
available in the Supplementary material (Table S1).
Taking together the cancer cell line and drug stream, we used
827 features to build our predictive models of the log IC50 value of
a given cell line in the presence of a given drug.
Cross-validation
We used an 8-fold cross-validation for building our models.
Therefore, we separated the original dataset into eight equally
sized sets of IC50 values, obtained by randomly distributing all
IC50s of the matrix into 8 bins. One of them was exclusively used
for testing (never involved in any training), other six were destined
for training the model and the remaining piece was used for cross-
Predicting Drug Effect from Genomics and Chemistry
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overfitting [36] e.g. identifying the optimal number of hidden units
and training iterations for a neural network (details in ‘‘Machine
learning’’ section). We rotated iteratively the sets so that each data
point was used at least once for training, cross-training or testing.
Finally, we obtained 8 models, which were equally predictive.
Furthermore, we used a more stringent version of the above
described 8-fold cross-validation. We ensured that test, train and
cross-train set are not sharing any cell line, which might occur in
the non-stringent version (described above). For instance, assume
cell line C1 is treated with the drugs D1, D2 and D3; For the non-
stringent cross-validation, the combination C1–D1, C1–D2 and
C1–D3 might be distributed over test, train and cross-train set; for
the stringent cross-validation, every combination with C1 is
exclusively occurring in one of those three sets.
Machine learning
For the neural networks, we used the Java implementation from
Encog 3.0.1 (http://www.heatonresearch.com/encog) [37,38] of a
feed-forward multi layer perceptron, where we defined three
different layers: input, hidden (or middle) and output layer. Every
perceptron of a layer is completely connected to each perceptron
of the upper layer. The number of features determined the
number of input units, or put it differently, required perceptrons in
the first layer. The number of hidden units was explored during
the training for determining the correct model complexity, which
was between 1 and 30 hidden units. Furthermore, each input and
hidden unit had also an bias, which is a permanent activation
input for those perceptrons. We used a single output unit for
predicting the continuous log(IC50) value.
As perceptron activation function for enabling the network to
predict non-linear behaviour, we used the sigmoid function, which
returns values in an interval from 0 to 1. Therefore, we had to
normalise the IC50 values (raw IC50 values, not in log space) also
into a range from 0 to 1, which was done with the following
logistic-like function:
norm y ðÞ ~
1
1zy{0:1 where yw0
y: Observed/expected IC50 value, which has to be a positive
number greater than zero.
We trained the network with the resilient error backpropagation
implementation from Encog with default parameters [39]. For
exploring the final model complexity, which is described by
number of hidden units and amount of training iterations, we
examined different neural network architectures from 1 up to 30
hidden units and trained them for maximal 400 iterations. We
searched the global minimum in that cross-training landscape
(minimizing the root mean square error of cross training set) for
avoiding an under- or overfitting (usually, between 21 and 27
hidden units were chosen as best model after approximately 300
iterations).
We also carried out random forest [40] regression models to
investigate whether there was any significant performance gain
using an alternative non-parametric machine learning methodol-
ogy (Text S3). A random forest is an ensemble of many different
regression trees randomly generated from the same training data
(recommended value of n=500 trees was used).
Data access
The dataset is fully accessible of the Genomics of Drug
Sensitivity in Cancer project [3], downloaded from the project
website, http://www.cancerrxgene.org/. The training set is based
on release v1.0 from June 2012. Newly generated IC50 values of
the blind test are published in release v1.1 from July 2012, which
are not part of Release v1.0.
Software access
The Encog Machine Learning Framework (version 3.0.1)
[37,38] containing the neural network implementation is a free
available and open source (Apache License 2.5), and could be
downloaded on the Heaton Research webpage (http://www.
heatonresearch.com/encog). For the random forest model, the R
package randomForest (version 4.6–6) [41] is also freely available
under GPL licence from CRAN webpage (http://cran.r-project.
org/web/packages/randomForest/index.html).
Supporting Information
Figure S1 Blind test of multi-drug model. The training
dataset holds 38,930 IC50 values, that is ,58% of all possible
drug-to-cell line combinations. For the blind test, 13,565 novel
IC50 values were generated, an,18% additional data points which
were not included in the training dataset. For obtaining the
predicted log(IC50) values, we averaged the output of each model
(8 different models resulting from the 8-fold cross-validation
procedure). The prediction on the blind test was slightly worse
than that estimated by cross-validation (Fig 3A): root mean square
error (RMSE) was increased from 0.83 to 0.97, coefficient of
determination (R
2) declined from 0.72 to 0.64 and the Pearson
correlation coefficient (Rp) was decreased from 0.85 to 0.79. This
small performance decrease is due to the fact that blind test data
points are not selected at random: these tend to come from drug-
cell combinations that are not optimally represented in the
training set (i.e. those cell lines in the training set that have been
probed against every drug in the panel will not have further IC50
values in the test set, as all training and test sets in this study are
non-overlapping).
(TIFF)
Figure S2 Correlation between predicted to experimen-
tal observed log(IC50) values leaving out cell lines. The
stringent 8-fold cross-validation was performed on the distinct set
of cell lines, so that a cell line was neither used for testing or
involved in the training. The figure shows values obtained solely
on the test sets. The prediction quality is slightly worse than the
normal cross-validation (Figure 3A): RMSE increased from 0.83 to
0.89, R
2 decreased from 0.72 to 0.68 and the Rp decreased from
0.85 to 0.82.
(TIFF)
Figure S3 Correlation between predicted to experimen-
tal observed log(IC50) values leaving out all lung cell
lines. To further challenge our model and our hypothesis that it is
possible to leave out several cell lines, we removed all lung cell
lines and used them exclusively for testing. There are 106 out of
608 cell lines are from lung tissue (,17% from data), which we
were able to predict with minor performance reduction compared
to including all cell lines (Figure 3A): root mean square error
(RMSE) increased from 0.83 to 0.99, coefficient of determination
(R
2) declined from 0.72 to 0.61 and the Pearson correlation
coefficient (Rp) decreased from 0.85 to 0.79.
(TIFF)
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